Research programme: serotonin 3 receptor modulators - AMRI

Drug Profile

Research programme: serotonin 3 receptor modulators - AMRI

Alternative Names: 5-HT3 receptor antagonists - AMRI; 5-HT3 receptor partial agonists - AMRI; ALB-137391(a); AMR-SER-67

Latest Information Update: 09 Sep 2016

Price : $50

At a glance

  • Originator AMRI
  • Class Benzoxazoles; Indazoles; Indoles
  • Mechanism of Action Serotonin 3 receptor antagonists; Serotonin 3 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Irritable bowel syndrome

Most Recent Events

  • 09 Sep 2016 AMRI's serotonin 3 receptor modulator programme is still in preclinical development for Irritable bowl syndrome (AMRI pipeline, September 2016)
  • 12 Oct 2010 AMRI's serotonin 3 receptor modulator programme is available for licensing http://www.amriglobal.com/index.cfm
  • 12 Oct 2010 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top